Lymphoma & Myeloma 2010

6:15 am	Breakfast symposium: To the Bone Marrow…And Beyond! Optimizing Bone-Related and Anti Tumor Properties of Bisphosphonates for Patients with Multiple Myeloma Supported by Novartis Oncology
8:00 am	Welcome
8:05 am	Introduction Morton Coleman, MD
Session VI: Myeloma and Lymphoproliferative Malignancies: Emerging Agents on Their Way to a Pharmacy Near You Moderator: Asher Chanan-Khan, MD
8:10 am	Key signal transduction pathways in lymphoma Ronald Gartenhaus, MD
8:30 am	Novel IMiDs compounds Asher Chanan-Khan, MD
8:45 am	Novel proteasome inhibitors Ruben Niesvizky, MD
9:00 am	Novel chemotherapeutic agents Owen O’Connor, MD, PhD
9:15 am	Novel monoclonal antibodies Myron Czuczman, MD, PhD
9:30 am	Panel discussion
9:40 am	Coffee break
Session VII: Waldenstrom’s Macroglobulinemia Moderator: Morton Coleman, MD
10:00 am	The Bruce Waterfall Memorial Lecture: What is the best frontline treatment? Irene Ghobrial, MD
10:30 am	What is the best treatment for relapsed disease? Roger G. Owen, MD
10:50 am	Novel approaches to WM Richard R. Furman, MD
11:10 am	Complications of high IgM - cryoglobulins and hyperviscosity: Plasmapheresis – when is it indicated and how effective is it in both WM and myeloma? Peter Martin, MD
11:30 am	Panel discussion
11:45 am	Lunch symposium: Translating Clinical Trial Data into Clinical Pratice: Expert Roundtable Discussion of Management Considerations in Hematologic Malignancies Supported by Celgene Corporation

Session VIII: From Bench to Bedside Moderator: Richard R. Furman, MD
1:45 pm	Biology of CLL Thomas Kipps, MD
2:05 pm	Biochemical pathways: Targets to be exploited? Richard R. Furman, MD
2:25 pm	Making the diagnosis: Is monoclonal B cell lymphocytosis a real entity? Tait D. Shanafelt, MD
2:45 pm	Response evaluation: Is a complete remission necessary or just a surrogate marker for good prognosis? Michael J. Keating, MB, BS
3:05 pm	Coffee break
Session IX: Special Presentations Moderator: Morton Coleman, MD
3:25 pm	The SASS Foundation for Medical Research Award Ceremony Francis P. Arena, MD - President & Director of Research for the SASS Foundation Presentation: John Ultmann Award for Contributions to CLL Research Presenters: Richard R. Furman, MD and Morton Coleman, MD Recipient: Kanti Rai, MD
3:35 pm	Prognostic factors: Do they have a role in treatment decisions and timing? Kanti Rai, MD
Session X: CLL Treatment Moderator: Michael J. Keating, MB, BS
3:55 pm	What is the best frontline approach to treatment? Neil Kay, MD
4:15 pm	What is the best approach for patients who relapse? Asher Chanan-Khan, MD
4:35 pm	Panel discussion
4:45 pm	Adjourn